Candel Therapeutics (CADL) Total Non-Current Liabilities (2020 - 2023)
Historic Total Non-Current Liabilities for Candel Therapeutics (CADL) over the last 4 years, with Q3 2023 value amounting to $26.6 million.
- Candel Therapeutics' Total Non-Current Liabilities fell 583.28% to $26.6 million in Q3 2023 from the same period last year, while for Sep 2023 it was $26.6 million, marking a year-over-year decrease of 583.28%. This contributed to the annual value of $28.1 million for FY2022, which is 31219.19% up from last year.
- Per Candel Therapeutics' latest filing, its Total Non-Current Liabilities stood at $26.6 million for Q3 2023, which was down 583.28% from $26.9 million recorded in Q2 2023.
- In the past 5 years, Candel Therapeutics' Total Non-Current Liabilities registered a high of $28.3 million during Q3 2022, and its lowest value of $5.5 million during Q3 2021.
- Its 4-year average for Total Non-Current Liabilities is $19.7 million, with a median of $26.6 million in 2023.
- In the last 5 years, Candel Therapeutics' Total Non-Current Liabilities surged by 41156.98% in 2022 and then tumbled by 583.28% in 2023.
- Quarter analysis of 4 years shows Candel Therapeutics' Total Non-Current Liabilities stood at $6.0 million in 2020, then rose by 14.5% to $6.8 million in 2021, then soared by 312.19% to $28.1 million in 2022, then fell by 5.3% to $26.6 million in 2023.
- Its last three reported values are $26.6 million in Q3 2023, $26.9 million for Q2 2023, and $26.4 million during Q1 2023.